188 related articles for article (PubMed ID: 16739341)
1. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.
Forrer F; Waldherr C; Maecke HR; Mueller-Brand J
Anticancer Res; 2006; 26(1B):703-7. PubMed ID: 16739341
[TBL] [Abstract][Full Text] [Related]
2. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
Bodei L; Cremonesi M; Grana C; Rocca P; Bartolomei M; Chinol M; Paganelli G
Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):1038-46. PubMed ID: 15150675
[TBL] [Abstract][Full Text] [Related]
3. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Waldherr C; Pless M; Maecke HR; Schumacher T; Crazzolara A; Nitzsche EU; Haldemann A; Mueller-Brand J
J Nucl Med; 2002 May; 43(5):610-6. PubMed ID: 11994522
[TBL] [Abstract][Full Text] [Related]
4. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
[TBL] [Abstract][Full Text] [Related]
5. Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue.
Waldherr C; Haldemann A; Maecke HR; Crazzolara A; Mueller-Brand J
Clin Oncol (R Coll Radiol); 2000; 12(2):121-3. PubMed ID: 10853753
[TBL] [Abstract][Full Text] [Related]
6. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
Bodei L; Handkiewicz-Junak D; Grana C; Mazzetta C; Rocca P; Bartolomei M; Lopera Sierra M; Cremonesi M; Chinol M; Mäcke HR; Paganelli G
Cancer Biother Radiopharm; 2004 Feb; 19(1):65-71. PubMed ID: 15068613
[TBL] [Abstract][Full Text] [Related]
7. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients.
Paganelli G; Zoboli S; Cremonesi M; Mäcke HR; Chinol M
Cancer Biother Radiopharm; 1999 Dec; 14(6):477-83. PubMed ID: 10850334
[TBL] [Abstract][Full Text] [Related]
8. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
[TBL] [Abstract][Full Text] [Related]
9. [Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].
Otte A; Herrmann R; Mäcke HR; Müller-Brand J
Praxis (Bern 1994); 1999 Aug; 88(31-32):1263-8. PubMed ID: 10479965
[TBL] [Abstract][Full Text] [Related]
10. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Valkema R; Pauwels S; Kvols LK; Barone R; Jamar F; Bakker WH; Kwekkeboom DJ; Bouterfa H; Krenning EP
Semin Nucl Med; 2006 Apr; 36(2):147-56. PubMed ID: 16517236
[TBL] [Abstract][Full Text] [Related]
11. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.
Waldherr C; Pless M; Maecke HR; Haldemann A; Mueller-Brand J
Ann Oncol; 2001 Jul; 12(7):941-5. PubMed ID: 11521799
[TBL] [Abstract][Full Text] [Related]
12. Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?
Cybulla M; Weiner SM; Otte A
Med Sci Monit; 2002 Apr; 8(4):LE7. PubMed ID: 11951054
[No Abstract] [Full Text] [Related]
13. Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity.
Vinjamuri S; Gilbert TM; Banks M; McKane G; Maltby P; Poston G; Weissman H; Palmer DH; Vora J; Pritchard DM; Cuthbertson DJ
Br J Cancer; 2013 Apr; 108(7):1440-8. PubMed ID: 23492685
[TBL] [Abstract][Full Text] [Related]
14. Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial.
Pless M; Waldherr C; Maecke H; Buitrago C; Herrmann R; Mueller-Brand J
Lung Cancer; 2004 Sep; 45(3):365-71. PubMed ID: 15301877
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
16. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide.
Paganelli G; Zoboli S; Cremonesi M; Bodei L; Ferrari M; Grana C; Bartolomei M; Orsi F; De Cicco C; Mäcke HR; Chinol M; de Braud F
Eur J Nucl Med; 2001 Apr; 28(4):426-34. PubMed ID: 11357492
[TBL] [Abstract][Full Text] [Related]
17. 90Y-DOTATOC and nephrotoxicity.
Otte A; Cybulla M; Weiner SM
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1543. PubMed ID: 12537003
[No Abstract] [Full Text] [Related]
18. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
19.
Menda Y; Madsen MT; O'Dorisio TM; Sunderland JJ; Watkins GL; Dillon JS; Mott SL; Schultz MK; Zamba GKD; Bushnell DL; O'Dorisio MS
J Nucl Med; 2018 Nov; 59(11):1692-1698. PubMed ID: 29523629
[TBL] [Abstract][Full Text] [Related]
20. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Bushnell D; Menda Y; O'Dorisio T; Madsen M; Miller S; Carlisle T; Squires S; Kahn D; Walkner W; Connolly M; O'Dorisio S; Karwal M; Ponto J; Bouterfa H
Cancer Biother Radiopharm; 2004 Feb; 19(1):35-41. PubMed ID: 15068609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
